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Chronic obstructive pulmonary disease (COPD) remains a major
public health problem. It is the fourth leading cause of chronic
morbidity andmortality in theUnitedStates, and is projected to rank
fifth in 2020 in burden of disease worldwide, according to a study
published by the World Bank/World Health Organization. Yet,
COPD remains relatively unknown or ignored by the public as well
as public health and government officials. In 1998, in an effort to
bringmore attention to COPD, its management, and its prevention,
a committed groupof scientists encouraged theU.S.NationalHeart,
Lung, and Blood Institute and the World Health Organization to
form the Global Initiative for Chronic Obstructive Lung Disease
(GOLD). Among the important objectives of GOLD are to increase
awareness of COPD and to help the millions of people who suffer
from this disease and die prematurely of it or its complications. The
first step in the GOLD program was to prepare a consensus report,
Global Strategy for the Diagnosis, Management, and Prevention of
COPD, published in 2001. The present, newly revised document
follows the same format as the original consensus report, but has
been updated to reflect the many publications on COPD that have
appeared. GOLD national leaders, a network of international
experts, have initiated investigations of the causes and prevalence
of COPD in their countries, and developed innovative approaches
for the dissemination and implementation of COPD management
guidelines. We appreciate the enormous amount of work the GOLD
national leaders have done on behalf of their patients with COPD.
Despite the achievements in the 5 years since the GOLD report was
originally published, considerable additional work is ahead of us if
we are to control this major public health problem. The GOLD
initiative will continue to bring COPD to the attention of govern-
ments, public health officials, health care workers, and the general
public, but a concerted effort by all involved in health care will be
necessary.
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INTRODUCTION
Chronic obstructive pulmonary disease (COPD) is a major
cause of chronic morbidity and mortality throughout the world.
Many people suffer from this disease for years and die pre-
maturely of it or its complications. The goals of the Global
Initiative for Chronic Obstructive Lung Disease (GOLD) are to
improve prevention and management of COPD through a con-
certed worldwide effort of people involved in all facets of health
care and health care policy, and to encourage an expanded level
of research interest in this highly prevalent disease.
One strategy to help achieve the objectives of GOLD is to
provide health care workers, health care authorities, and the
general public with state-of-the-art information about COPD
and specific recommendations on the most appropriate man-
agement and prevention strategies. The GOLD report, Global
Strategy for the Diagnosis, Management, and Prevention of
COPD, is based on the best-validated current concepts of
COPD pathogenesis and the available evidence on the most
appropriate management and prevention strategies. A major
part of the GOLD report is devoted to the clinical management
of COPD and presents a management plan with four compo-
nents: (1) assess and monitor disease, (2) reduce risk factors, (3)
manage stable COPD, and (4) manage exacerbations. A new
section at the end of the document will assist readers in
translating guideline recommendations to the context of (pri-
mary) care.
GOLD is a partner organization in a program launched in
March 2006 by the World Health Organization’s Global Alli-
ance Against Chronic Respiratory Diseases (GARD). Through
the work of the GOLD committees, and in cooperation with
GARD initiatives, progress toward better care for all patients
with COPD should be substantial in the next decade.
Methodology and Summary of New Recommendations
After the release of the 2001 GOLD report, a science commit-
tee was formed and charged with keeping the GOLD docu-
ments up-to-date by reviewing published research, evaluating
the impact of this research on the management recommenda-
tions in the GOLD documents, and posting yearly updates of
these documents on the GOLD website (www.goldcopd.org).
The methodology is described in each update (see, e.g., the 2005
update in Reference 3 and the APPENDIX in the online supple-
ment).
In January 2005, the GOLD science committee initiated
preparation of this revised 2006 document on the basis of the
most current scientific literature. Multiple meetings were held,
including several with GOLD national leaders to discuss con-
cepts and new recommendations. Before its publications, sev-
eral reviewers were invited to submit comments.
A summary of the issues presented in this report include the
following:
1. Recognition that COPD is characterized by chronic
airflow limitation and a range of pathologic changes in
the lung, some significant extrapulmonary effects, and
important comorbidities that may contribute to the se-
verity of the disease in individual patients.
2. In the definition of COPD, the phrase ‘‘preventable and
treatable’’ has been incorporated following the American
Thoracic Society/European Respiratory Society recom-
mendations to recognize the need to present a positive
outlook for patients, to encourage the health care com-
munity to take a more active role in developing programs
for COPD prevention, and to stimulate effective manage-
ment programs to treat those with the disease.
3. The spirometric classification of severity of COPD now
includes four stages: stage I, mild; stage II, moderate;
stage III, severe; stage IV, very severe. A fifth category,
‘‘stage 0, at risk,’’ that appeared in the 2001 report is no
longer included as a stage of COPD, as there is in-
complete evidence that the individuals who meet the
definition of ‘‘at risk’’ (chronic cough and sputum pro-
duction, normal spirometry) necessarily progress on to
stage I. Nevertheless, the importance of the public health
message that chronic cough and sputum are not normal is
unchanged.
4. The spirometric classification of severity continues to
recommend use of the fixed ratio post-bronchodilator
FEV1/FVC , 0.7 to define airflow limitation. Using the
fixed ratio (FEV1/FVC) is particularly problematic in
patients with milder disease who are elderly because the
normal process of aging affects lung volumes. Post-
bronchodilator reference values in this population are
urgently needed to avoid potential overdiagnosis.
5. Section 2, BURDEN OF COPD, provides references to
published data from prevalence surveys to estimate that
about 15 to 25% of adults aged 40 years and older may
have airflow limitation classified as stage I mild COPD or
higher and that the prevalence of COPD (stage I, mild
COPD and higher) is appreciably higher in smokers and
ex-smokers than in nonsmokers, in those over 40 years
compared with those younger than 40, and higher in men
than in women. The section also provides new data on
COPD morbidity and mortality.
6. Cigarette smoke is the most commonly encountered risk
factor for COPD and elimination of this risk factor is an
important step toward prevention and control of COPD.
However, other risk factors for COPD should be taken
into account where possible, including occupational
dusts and chemicals, and indoor air pollution from
biomass cooking and heating in poorly ventilated dwell-
ings—the latter especially among women in developing
countries.
7. The section on pathology, pathogenesis, and pathophys-
iology, continues with the theme that inhaled cigarette
smoke and other noxious particles cause lung inflamma-
tion, a normal response which appears to be amplified in
patients who develop COPD. The section has been
considerably updated and revised.
8. Management of COPD continues to be presented in four
components: (1) assess and monitor disease, (2) reduce
risk factors, (3) manage stable COPD, and (4) manage
exacerbations. All components have been updated on the
basis of recently published literature. Throughout it is
emphasized that the overall approach to managing stable
COPD should be individualized to address symptoms and
improve quality of life.
9. In COMPONENT 4, MANAGE EXACERBATIONS, a COPD
exacerbation is defined as ‘‘an event in the natural course
of the disease characterized by a change in the patient’s
baseline dyspnea, cough, and/or sputum that is beyond
normal day-to-day variations, is acute in onset, and may
warrant a change in regular medication in a patient with
underlying COPD.’’
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10. It is widely recognized that a wide spectrum of health
care providers is required to ensure that COPD is
diagnosed accurately, and that individuals who have
COPD are treated effectively. The identification of
effective health care teams will depend on the local
health care system, and much work remains to identify
how best to build these health care teams. A section on
COPD implementation programs and issues for clinical
practice has been included but it remains a field that
requires considerable attention.
Levels of Evidence
Levels of evidence are assigned to management recommen-
dations where appropriate in subsections of section 3 that
discuss COPD management, with the system used in previous
GOLD reports (Table 1). Evidence levels are enclosed
in parentheses after the relevant statement—for example,
(Evidence A).
1. DEFINITION, CLASSIFICATION OF SEVERITY, AND
MECHANISMS OF COPD
Definition
Chronic obstructive pulmonary disease (COPD) is a preventable and
treatable disease with some significant extrapulmonary effects that
may contribute to the severity in individual patients. Its pulmonary
component is characterized by airflow limitation that is not fully
reversible. The airflow limitation is usually progressive and associ-
ated with an abnormal inflammatory response of the lung to noxious
particles or gases.
The chronic airflow limitation characteristic of COPD is
caused by a mixture of small airway disease (obstructive
bronchiolitis) and parenchymal destruction (emphysema), the
relative contributions of which vary from person to person.
Airflow limitation is best measured by spirometry, because this
is the most widely available, reproducible test of lung function.
Because COPD often develops in longtime smokers in
middle age, patients often have a variety of other diseases
related to either smoking or aging (4). COPD itself also has
significant extrapulmonary (systemic) effects that lead to
comorbid conditions (5). Thus, COPD should be managed with
careful attention also paid to comorbidities and their effect on
the patient’s quality of life. A careful differential diagnosis and
comprehensive assessment of severity of comorbid conditions
should be performed in every patient with chronic airflow
limitation.
Spirometric Classification of Severity and Stages of COPD
For educational reasons, a simple spirometric classification of
disease severity into four stages is recommended (Table 2).
Spirometry is essential for diagnosis and provides a useful
description of the severity of pathologic changes in COPD.
Specific spirometric cut points (e.g., post-bronchodilator FEV1/
FVC ratio , 0.70 or FEV1 , 80, 50, or 30% predicted) are used
for purposes of simplicity; these cut points have not been
clinically validated. A study in a random population sample
found that the post-bronchodilator FEV1/FVC exceeded 0.70 in
all age groups, supporting the use of this fixed ratio (6). How-
ever, because the process of aging does affect lung volumes, the
use of this fixed ratio may result in overdiagnosis of COPD in
the elderly, especially in those with mild disease.
The characteristic symptoms of COPD are chronic and
progressive dyspnea, cough, and sputum production. Chronic
cough and sputum production may precede the development of
airflow limitation by many years. This pattern offers a unique
opportunity to identify smokers and others at risk for COPD,
and to intervene when the disease is not yet a major health
problem. Conversely, significant airflow limitation may develop
without chronic cough and sputum production.
Stage I: mild COPD: Characterized by mild airflow limitation
(FEV1/FVC , 0.70, FEV1 > 80% predicted). Symptoms of
chronic cough and sputum production may be present, but
not always. At this stage, the individual is usually unaware
that his or her lung function is abnormal.
Stage II: moderate COPD: Characterized by worsening airflow
limitation (FEV1/FVC , 0.70, 50% < FEV1 , 80% pre-
dicted), with shortness of breath typically developing on
exertion and cough and sputum production sometimes also
present. This is the stage at which patients typically seek
medical attention because of chronic respiratory symptoms
or an exacerbation of their disease.
Stage III: severe COPD: Characterized by further worsening of
airflow limitation (FEV1/FVC , 0.70, 30% < FEV1 , 50%
predicted), greater shortness of breath, reduced exercise
capacity, fatigue, and repeated exacerbations that almost
always have an impact on patients’ quality of life.
TABLE 1. DESCRIPTION OF LEVELS OF EVIDENCE
Evidence
Category Sources of Evidence Definition
A RCTs. Rich body of data. Evidence is from endpoints of well-designed RCTs that provide a consistent pattern of findings
in the population for which the recommendation is made. Category A requires substantial numbers
of studies involving substantial numbers of participants.
B RCTs. Limited body of data. Evidence is from endpoints of intervention studies that include only a limited number of patients,
post hoc or subgroup analysis of RCTs, or meta-analysis of RCTs. In general, category B pertains
when few randomized trials exist, they are small in size, they were undertaken in a population
that differs from the target population of the recommendation, or the results are somewhat
inconsistent.
C Nonrandomized trials.
Observational studies.
Evidence is from outcomes of uncontrolled or nonrandomized trials or from observational studies.
D Panel consensus judgment. This category is used only in cases where the provision of some guidance was deemed valuable but
the clinical literature addressing the subject was insufficient to justify placement in one of the
other categories. The panel consensus is based on clinical experience or knowledge that does not
meet the above-listed criteria.
Definition of abbreviation: RCT 5 randomized controlled trial.
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Stage IV: very severe COPD: Characterized by severe airflow
limitation (FEV1/FVC , 0.70, FEV1 , 30% predicted or
FEV1 , 50% predicted plus the presence of chronic re-
spiratory failure). Respiratory failure is defined as an arterial
partial pressure of O2 (PaO2) less than 8.0 kPa (60 mm Hg),
with or without an arterial partial pressure of CO2 (PaCO2)
greater than 6.7 kPa (50 mm Hg) while breathing air at sea
level. Respiratory failure may also lead to effects on the heart
such as cor pulmonale (right heart failure). Clinical signs of
cor pulmonale include elevation of the jugular venous
pressure and pitting ankle edema. Patients may have stage
IV COPD even if their FEV1 is greater than 30% predicted,
whenever these complications are present. At this stage,
quality of life is very appreciably impaired and exacerbations
may be life threatening.
Although asthma can usually be distinguished from COPD,
in some individuals with chronic respiratory symptoms and fixed
airflow limitation it remains difficult to differentiate the two
diseases. In many developing countries, both pulmonary tuber-
culosis and COPD are common (7). In countries where tuber-
culosis is very common, respiratory abnormalities may be too
readily attributed to this disease (8). Conversely, where the rate
of tuberculosis is greatly diminished, the possible diagnosis of
this disease is sometimes overlooked. Therefore, in all subjects
with symptoms of COPD, a possible diagnosis of tuberculosis
should be considered, especially in areas where this disease is
known to be prevalent (9).
Pathology, Pathogenesis, and Pathophysiology
Pathologic changes characteristic of COPD are found in the
proximal airways, peripheral airways, lung parenchyma, and
pulmonary vasculature (10). The pathologic changes include
chronic inflammation, with increased numbers of specific in-
flammatory cell types in different parts of the lung, and struc-
tural changes resulting from repeated injury and repair. In
general, the inflammatory and structural changes in the airways
increase with disease severity and persist on smoking cessation.
The inflammation in the respiratory tract of patients with
COPD appears to be an amplification of the normal inflamma-
tory response of the respiratory tract to chronic irritants such as
cigarette smoke. The mechanisms for this amplification are not
yet understood but may be genetically determined. Some pa-
tients develop COPD without smoking, but the nature of the
inflammatory response in these patients is unknown (11). Lung
inflammation is further amplified by oxidative stress and an
excess of proteinases in the lung. Together, these mechanisms
lead to the characteristic pathologic changes in COPD.
There is now a good understanding of how the underlying
disease process in COPD leads to the characteristic physiologic
abnormalities and symptoms. For example, decreased FEV1
primarily results from inflammation and narrowing of periph-
eral airways and a dynamic airway collapse in more severe
emphysema, whereas decreased gas transfer arises from the
parenchymal destruction of emphysema. The extent of inflam-
mation, fibrosis, and luminal exudates in small airways is
correlated with the reduction in FEV1 and FEV1/FVC ratio,
and probably with the accelerated decline in FEV1 character-
istic of COPD (4). Gas exchange abnormalities result in hy-
poxemia and hypercapnia, and have several mechanisms in
COPD. In general, gas transfer worsens as the disease pro-
gresses. Mild to moderate pulmonary hypertension may develop
late in the course of COPD and is due to hypoxic vasoconstric-
tion of small pulmonary arteries. It is increasingly recognized
that COPD involves several systemic features, particularly in
patients with severe disease, and that these have a major impact
on survival and comorbid diseases (12, 13).
2. BURDEN OF COPD
COPD prevalence, morbidity, and mortality vary across coun-
tries and across different groups within countries but, in general,
are directly related to the prevalence of tobacco smoking,
although, in many countries, air pollution resulting from the
burning of wood and other biomass fuels has also been
identified as a COPD risk factor. The prevalence and burden
of COPD are projected to increase in the coming decades due
to continued exposure to COPD risk factors and the changing
age structure of the world’s population.
Epidemiology
In the past, imprecise and variable definitions of COPD have
made it difficult to quantify prevalence, morbidity, and mortal-
ity. Furthermore, the underrecognition and underdiagnosis of
COPD lead to significant underreporting. The extent of the
underreporting varies across countries and depends on the level
of awareness and understanding of COPD among health
professionals, the organization of health care services to cope
with chronic diseases, and the availability of medications for the
treatment of COPD (14).
Prevalence. Many sources of variation can affect estimates of
COPD prevalence, including sampling methods, response rates,
quality control of spirometry, and whether spirometry is per-
formed pre- or post-bronchodilator. Despite these complexities,
data are emerging that enable some conclusions to be drawn
regarding COPD prevalence. A prevalence study in Latin
America (19), a systematic review and meta-analysis of studies
performed in 28 countries between 1990 and 2004 (15), and
an additional study from Japan (16) provide evidence that the
prevalence of COPD (stage I, mild COPD and higher) is
appreciably higher in smokers and ex-smokers compared with
nonsmokers, in those older than 40 years compared with those
younger than 40 years, and in men compared with women.
Morbidity. Morbidity measures traditionally include physi-
cian visits, emergency department visits, and hospitalizations.
Although COPD databases for these outcome parameters are
less readily available and usually less reliable than mortality
databases, the limited data available indicate that morbidity due
to COPD increases with age and is greater in men than in
women (17, 18). COPD in its early stages (stages I and II) is
usually not recognized, diagnosed, or treated, and therefore
may not be included as a diagnosis in a patient’s medical record.
Morbidity from COPD may be affected by other comorbid
chronic conditions (20) (e.g., musculoskeletal disease, diabetes
TABLE 2. SPIROMETRIC CLASSIFICATION OF CHRONIC
OBSTRUCTIVE PULMONARY DISEASE SEVERITY BASED ON
POST-BRONCHODILATOR FEV1
Stage I: mild FEV1/FVC , 0.70
FEV1 > 80% predicted
Stage II: moderate FEV1/FVC , 0.70
50% < FEV1 , 80% predicted
Stage III: severe FEV1/FVC , 0.70
30% < FEV1 , 50% predicted
Stage IV: very severe FEV1/FVC , 0.70
FEV1 , 30% predicted or FEV1 , 50%
predicted plus chronic respiratory failure*
* Respiratory failure: arterial partial pressure of oxygen (PaO2) , 8.0 kPa
(60 mm Hg) with or without arterial partial pressure of CO2 (PaCO2) . 6.7 kPa
(50 mm Hg) while breathing air at sea level.
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mellitus) that are not directly related to COPD but nevertheless
may have an impact on the patient’s health status, or may in-
terfere with COPD management. In patients with more
advanced disease (stages III and IV), morbidity from COPD
may be misattributed to another comorbid condition.
Mortality. COPD is one of the most important causes of
death in most countries. The Global Burden of Disease Study
(2, 21, 22) has projected that COPD, which ranked sixth as the
cause of death in 1990, will become the third leading cause of
death worldwide by 2020. This increased mortality is driven by
the expanding epidemic of smoking and the changing demo-
graphics in most countries, with more of the population living
longer.
Economic and Social Burden of COPD
COPD is a costly disease. In developed countries, exacerbations
of COPD account for the greatest burden on the health care
system. In the European Union, the total direct costs of
respiratory disease are estimated to be about 6% of the total
health care budget, with COPD accounting for 56% (V38.6
billion) of this cost of respiratory disease (23). In the United
States in 2002, the direct costs of COPD were $18 billion and
the indirect costs totaled $14.1 billion (1). Costs per patient will
vary across countries because these costs depend on how health
care is provided and paid (24). Not surprisingly, there is
a striking direct relationship between the severity of COPD
and the cost of care (25), and the distribution of costs changes as
the disease progresses.
Risk Factors
Identification of cigarette smoking as the most commonly
encountered risk factor for COPD has led to the incorporation
of smoking cessation programs as a key element of COPD
prevention, as well as an important intervention for patients
who already have the disease. However, although smoking is
the best-studied COPD risk factor, it is not the only one and
there is consistent evidence from epidemiologic studies that
nonsmokers may develop chronic airflow obstruction (26, 27)
(Figure 1).
Genes. As the understanding of the importance of risk
factors for COPD has grown, so has the recognition that
essentially all risk for COPD results from a gene–environment
interaction. The genetic risk factor that is best documented is
a severe hereditary deficiency of a1-antitrypsin (28), a major
circulating inhibitor of serine proteases. This rare recessive trait
is most commonly seen in individuals of northern European
origin (29).
Genetic association studies have implicated a variety of genes
in COPD pathogenesis. However, the results of these genetic
association studies have been largely inconsistent, and functional
genetic variants influencing the development of COPD (other
than a1-antitrypsin deficiency) have not been definitively identi-
fied (30).
Inhalational exposures. TOBACCO SMOKE. Cigarette smokers
have a higher prevalence of respiratory symptoms and lung
function abnormalities, a greater annual rate of decline in
FEV1, and a greater COPD mortality rate than nonsmokers.
Pipe and cigar smokers have greater COPD morbidity and
mortality rates than nonsmokers, although their rates are lower
than those for cigarette smokers (31). Other types of tobacco
smoking popular in various countries are also risk factors for
COPD (32, 33). Not all smokers develop clinically significant
COPD, which suggests that genetic factors must modify each
individual’s risk (34). Passive exposure to cigarette smoke may
also contribute to respiratory symptoms (35) and COPD (36) by
increasing the lungs’ total burden of inhaled particles and gases
(37, 38). Smoking during pregnancy may also pose a risk for the
fetus, by affecting lung growth and development in utero and
possibly the priming of the immune system (39, 40).
OCCUPATIONAL DUSTS AND CHEMICALS. Occupational expo-
sures include organic and inorganic dusts and chemical agents
and fumes. A statement published by the American Thoracic
Society concluded that occupational exposures account for 10 to
20% of either symptoms or functional impairment consistent
with COPD (41).
INDOOR AND OUTDOOR AIR POLLUTION. The evidence that
indoor pollution from biomass cooking and heating in poorly
ventilated dwellings is an important risk factor for COPD
(especially among women in developing countries) continues
to grow (42–48), with case-control studies (47, 48) and other
designed studies now available. High levels of urban air
pollution are harmful to individuals with existing heart or lung
disease, but the role of outdoor air pollution in causing COPD is
unclear.
Sex. Studies from developed countries (1, 49) show that
the prevalence of the disease is now almost equal in men and
Figure 1. Chronic obstructive pulmonary disease risk is
related to the total burden of inhaled particles.
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women, probably reflecting the changing patterns of tobacco
smoking. Some studies have suggested that women are more
susceptible to the effects of tobacco smoke than men (50–
52).
Infection. A history of severe childhood respiratory infec-
tion has been associated with reduced lung function and
increased respiratory symptoms in adulthood (53–55). How-
ever, susceptibility to viral infections may be related to
another factor, such as low birth weight, that itself is related
to COPD.
Socioeconomic status. There is evidence that the risk of
developing COPD is inversely related to socioeconomic status
(56). It is not clear, however, whether this pattern reflects
exposures to cigarette smoke, indoor and outdoor air pollutants,
crowding, poor nutrition, or other factors that are related to low
socioeconomic status (57, 58).
3. THE FOUR COMPONENTS OF COPD MANAGEMENT
Introduction
An effective COPD management plan includes four compo-
nents: (1) assess and monitor disease, (2) reduce risk factors, (3)
manage stable COPD, and (4) manage exacerbations. Although
disease prevention is the ultimate goal, once COPD has been
diagnosed, effective management should be aimed at the
following goals:
d Relieve symptoms
d Prevent disease progression
d Improve exercise tolerance
d Improve health status
d Prevent and treat complications
d Prevent and treat exacerbations
d Reduce mortality
These goals should be reached with minimal side effects from
treatment, a particular challenge in patients with COPD
because they commonly have comorbidities. The extent to
which these goals can be realized varies with each individual,
and some treatments will produce benefits in more than one
area. In selecting a treatment plan, the benefits and risks to
the individual, and the costs, direct and indirect, to the
individual, his or her family, and the community must be
considered.
Patients should be identified as early in the course of the
disease as possible, and certainly before the end stage of the
illness when disability is substantial. Access to spirometry is key
to the diagnosis of COPD and should be available to health care
workers who care for patients with COPD. However, the
benefits of community-based spirometric screening, of either
the general population or smokers, are still unclear.
Educating patients, physicians, and the public to recognize
that cough, sputum production, and especially breathlessness
are not trivial symptoms is an essential aspect of the public
health care of this disease.
Reduction of therapy once symptom control has been achieved
is not normally possible in COPD. Further deterioration of lung
function usually requires the progressive introduction of more
treatments, both pharmacologic and nonpharmacologic, to at-
tempt to limit the impact of these changes. Exacerbations of signs
and symptoms, a hallmark of COPD, impair patients’ quality of
life and decrease their health status. Appropriate treatment and
measures to prevent further exacerbations should be imple-
mented as quickly as possible.
Component 1: Assess and Monitor Disease
Initial diagnosis. A clinical diagnosis of COPD should be
considered in any patient who has dyspnea, chronic cough or
sputum production, and/or a history of exposure to risk factors
for the disease (Table 3). The diagnosis should be confirmed by
spirometry.
ASSESSMENT OF SYMPTOMS. Dyspnea, the hallmark symptom
of COPD, is the reason most patients seek medical attention
and is a major cause of disability and anxiety associated with the
disease. As lung function deteriorates, breathlessness becomes
more intrusive. Chronic cough, often the first symptom of
COPD to develop (59) and often predating the onset of dys-
pnea, may be intermittent, but later is present every day, often
throughout the day. In some cases, significant airflow limitation
may develop without the presence of a cough. Patients with
COPD commonly raise small quantities of tenacious sputum
after coughing bouts. Wheezing and chest tightness are non-
specific symptoms that may vary between days, and over the
course of a single day. An absence of wheezing or chest tight-
ness does not exclude a diagnosis of COPD. Weight loss, an-
orexia, and psychiatric morbidity, especially symptoms of de-
pression and/or anxiety, are common problems in advanced
COPD (60, 61).
MEDICAL HISTORY. A detailed medical history of a new pa-
tient known or believed to have COPD should assess the
following:
d Exposure to risk factors
KEY POINTS
d A clinical diagnosis of COPD should be considered in
any patient who has dyspnea, chronic cough or sputum
production, and/or a history of exposure to risk factors
for the disease. The diagnosis should be confirmed by
spirometry.
d For the diagnosis and assessment of COPD, spirometry
is the gold standard because it is the most reproducible,
standardized, and objective way of measuring airflow
limitation. A post-bronchodilator FEV1/FVC , 0.70
confirms the presence of airflow limitation that is not
fully reversible.
d Health care workers involved in the diagnosis and
management of patients with COPD should have access
to spirometry.
d Assessment of COPD severity is based on the patient’s
level of symptoms, the severity of the spirometric abnor-
mality, and the presence of complications.
d Measurement of arterial blood gas tensions should be
considered in all patients with FEV1 , 50% predicted or
clinical signs suggestive of respiratory failure or right
heart failure.
d COPD is usually a progressive disease and lung function
can be expected to worsen over time, even with the best
available care. Symptoms and objective measures of
airflow limitation should be monitored to determine
when to modify therapy and to identify any complica-
tions that may develop.
d Comorbidities are common in COPD and should be
actively identified. Comorbidities often complicate the
management of COPD, and vice versa.
GOLD Executive Summary 537
d Past medical history, including asthma, allergy, sinusitis, or
nasal polyps; respiratory infections in childhood; other
respiratory diseases
d Family history of COPD or other chronic respiratory
disease
d Pattern of symptom development
d History of exacerbations or previous hospitalizations for
respiratory disorder
d Presence of comorbidities, such as heart disease, malignan-
cies, osteoporosis, and muscloskeletal disorders, which may
also contribute to restriction of activity (62)
d Appropriateness of current medical treatments
d Impact of disease on patient’s life, including limitation of
activity, missed work and economic impact, effect on family
routines, feelings of depression or anxiety
d Social and family support available to the patient
d Possibilities for reducing risk factors, especially smoking
cessation
PHYSICAL EXAMINATION. Although an important part of pa-
tient care, a physical examination is rarely diagnostic in COPD.
Physical signs of airflow limitation are usually not present
until significant impairment of lung function has occurred (63,
64), and their detection has a relatively low sensitivity and
specificity.
MEASUREMENT OF AIRFLOW LIMITATION (SPIROMETRY). Spirom-
etry should be undertaken in all patients who may have COPD.
Spirometry should measure the volume of air forcibly exhaled
from the point of maximal inspiration (FVC) and the volume of
air exhaled during the first second of this maneuver (FEV1), and
the ratio of these two measurements (FEV1/FVC) should be
calculated. Spirometry measurements are evaluated by compar-
ison with reference values (65) based on age, height, sex, and
race (use appropriate reference values; e.g., see Reference 65).
Patients with COPD typically show a decrease in both FEV1
and FVC. The presence of airflow limitation is defined by
a post-bronchodilator FEV1/FVC , 0.70. This approach is
pragmatic in view of the fact that universally applicable
reference values for FEV1 and FVC are not available. Where
possible, values should be compared with age-related normal
values to avoid overdiagnosis of COPD in the elderly (66).
Using the fixed ratio (FEV1/FVC) is particularly problematic in
patients with milder COPD who are elderly because the normal
process of aging affects lung volumes.
ASSESSMENT OF COPD SEVERITY. Assessment of COPD
severity is based on the patient’s level of symptoms, the severity
of the spirometric abnormality (Table 2), and the presence of
complications such as respiratory failure, right heart failure,
weight loss, and arterial hypoxemia.
ADDITIONAL INVESTIGATIONS. For patients diagnosed with
stage II, moderate, COPD and beyond, the following additional
investigations may be considered.
Bronchodilator reversibility testing. Despite earlier hopes,
neither bronchodilator nor oral glucocorticosteroid reversibility
testing predicts disease progression, whether judged by decline
in FEV1, deterioration of health status, or frequency of exac-
erbations (67, 68) in patients with a clinical diagnosis of COPD
and abnormal spirometry (68). In some cases (e.g., a patient
with an atypical history such as asthma in childhood and regular
night waking with cough or wheeze), a clinician may wish to
perform a bronchodilator and/or glucocorticosteroid reversibil-
ity test.
Chest X-ray. An abnormal chest X-ray is seldom diagnostic
in COPD unless obvious bullous disease is present, but it is
valuable in excluding alternative diagnoses and establishing
the presence of significant comorbidities, such as cardiac
failure. Computed tomography (CT) of the chest is not
routinely recommended. However, when there is doubt about
the diagnosis of COPD, high-resolution CT scanning might
help in the differential diagnosis. In addition, if a surgical
procedure such as lung volume reduction is contemplated,
a chest CT scan is necessary because the distribution of
emphysema is one of the most important determinants of
surgical suitability (69).
Arterial blood gas measurement. In advanced COPD, mea-
surement of arterial blood gases while the patient is breathing
air is important. This test should be performed in stable patients
with FEV1 , 50% predicted or with clinical signs suggestive of
respiratory failure or right heart failure.
a1-Antitrypsin deficiency screening. In patients of Caucasian
descent who develop COPD at a young age (, 45 yr) or who
have a strong family history of the disease, it may be valuable to
identify coexisting a1-antitrypsin deficiency. This could lead to
family screening or appropriate counseling.
DIFFERENTIAL DIAGNOSIS. In some patients with chronic
asthma, a clear distinction from COPD is not possible using
current imaging and physiologic testing techniques, and it is
assumed that asthma and COPD coexist in these patients. In
these cases, current management is similar to that of asthma.
Other potential diagnoses are usually easier to distinguish from
COPD (Table 4).
Ongoing monitoring and assessment. MONITOR DISEASE PRO-
GRESSION AND DEVELOPMENT OF COMPLICATIONS. COPD is usually
a progressive disease. Lung function can be expected to worsen
over time, even with the best available care. Symptoms and
objective measures of airflow limitation should be monitored to
determine when to modify therapy and to identify any compli-
cations that may develop.
Follow-up visits should include a physical examination and
discussion of symptoms, particularly any new or worsening
symptoms. Spirometry should be performed if there is a sub-
stantial increase in symptoms or a complication. The develop-
ment of respiratory failure is indicated by a PaO2 , 8.0 kPa (60
mm Hg) with or without PaCO2. 6.7 kPa (50 mm Hg) in arterial
blood gas measurements made while breathing air at sea level.
Measurement of pulmonary arterial pressure is not recommen-
ded in clinical practice as it does not add practical information
beyond that obtained from a knowledge of PaO2.
TABLE 3. KEY INDICATORS FOR CONSIDERING A DIAGNOSIS
OF CHRONIC OBSTRUCTIVE PULMONARY DISEASE
Consider COPD, and perform spirometry, if any of these indicators are
present in an individual. These indicators are not diagnostic themselves,
but the presence of multiple key indicators increases the probability
of a diagnosis of COPD. Spirometry is needed to establish a diagnosis of COPD.
Dyspnea that is Progressive (worsens over time)
Usually worse with exercise
Persistent (present every day)
Described by the patient as an ‘‘increased
effort to breathe,’’ ‘‘heaviness,’’ ‘‘air hunger,’’
or ‘‘gasping
Chronic cough May be intermittent and may be unproductive
Chronic sputum production Any pattern of chronic sputum production
may indicate COPD
History of exposure
to risk factors, especially,
Tobacco smoke
Occupational dusts and chemicals
Smoke from home cooking and heating fuels
Definition of abbreviation: COPD 5 chronic obstructive pulmonary disease.
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MONITOR PHARMACOTHERAPY AND OTHER MEDICAL TREATMENT.
To adjust therapy appropriately as the disease progresses, each
follow-up visit should include a discussion of the current
therapeutic regimen. Dosages of various medications, adher-
ence to the regimen, inhaler technique, effectiveness of the
current regime at controlling symptoms, and side effects of
treatment should be monitored.
MONITOR EXACERBATION HISTORY. Frequency, severity, and
likely causes of exacerbations should be evaluated. Increased
sputum volume, acutely worsening dyspnea, and the presence of
purulent sputum should be noted. Severity can be estimated by
the increased need for bronchodilator medication or glucocor-
ticosteroids and by the need for antibiotic treatment. Hospital-
izations should be documented, including the facility, duration
of stay, and any use of critical care or intubation.
MONITOR COMORBIDITIES. Comorbidities are common in
COPD and may become harder to manage when COPD is
present, either because COPD adds to the total level of dis-
ability or because COPD therapy adversely affects the comor-
bid disorder. Until more integrated guidance about disease
management for specific comorbid problems becomes available,
the focus should be on identification and management of these
individual problems.
Component 2: Reduce Risk Factors
Smoking prevention and cessation. Comprehensive tobacco
control policies and programs with clear, consistent, and re-
peated nonsmoking messages should be delivered through every
feasible channel, including health care providers, community
activities, and schools, and radio, television, and print media.
Legislation to establish smoke-free schools, public facilities, and
work environments should be developed and implemented by
government officials and public health workers, and encouraged
by the public.
SMOKING CESSATION INTERVENTION PROCESS. Smoking cessa-
tion is the single most effective—and cost-effective—way to re-
duce exposure to COPD risk factors. All smokers—including
those who may be at risk for COPD as well as those who already
have the disease—should be offered the most intensive smoking
cessation intervention feasible. Even a brief (3 min) period of
counseling to urge a smoker to quit results in smoking cessation
rates of 5 to 10% (70). At the very least, this should be done for
every smoker at every health care provider visit (70, 71).
Guidelines for smoking cessation entitled ‘‘Treating Tobacco
Use and Dependence: A Clinical Practice Guideline’’ were
published by the U.S. Public Health Service (72) and recom-
mend a five-step program for intervention (Table 5), which
provides a strategic framework helpful to health care providers
interested in helping their patients stop smoking (72–75).
PHARMACOTHERAPY. Numerous effective pharmacotherapies
for smoking cessation now exist (72, 73, 76) (Evidence A), and
pharmacotherapy is recommended when counseling is not
sufficient to help patients quit smoking. Numerous studies
indicate that nicotine replacement therapy in any form (nicotine
gum, inhaler, nasal spray, transdermal patch, sublingual tablet,
or lozenge) reliably increases long-term smoking abstinence
rates (72, 77).
The antidepressants bupropion (78) and nortriptyline have
also been shown to increase long-term quit rates (76, 77, 79), but
should always be used as one element in a supportive in-
tervention program rather than on their own. The effectiveness
of the antihypertensive drug clonidine is limited by side effects
(77). Varenicline, a nicotinic acetylcholine receptor partial
TABLE 4. DIFFERENTIAL DIAGNOSIS OF CHRONIC OBSTRUCTIVE
PULMONARY DISEASE
Diagnosis Suggestive Features
COPD Onset in midlife
Symptoms slowly progressive
Long history of tobacco smoking
Dyspnea during exercise
Largely irreversible airflow limitation
Asthma Onset early in life (often childhood)
Symptoms vary from day to day
Symptoms at night/early morning
Allergy, rhinitis, and/or eczema also present
Family history of asthma
Largely reversible airflow limitation
Congestive heart failure Nonspecific basilar crackles on auscultation
Chest X-ray shows dilated heart, pulmonary edema
Pulmonary function tests indicate volume
restriction, not airflow limitation
Bronchiectasis Large volumes of purulent sputum
Commonly associated with bacterial infection
Coarse crackles/clubbing on auscultation
Chest X-ray/CT shows bronchial dilation,
bronchial wall thickening
Tuberculosis Onset all ages
Chest X-ray shows lung infiltrate
Microbiological confirmation
High local prevalence of tuberculosis
Obliterative bronchiolitis Onset in younger age, nonsmokers
May have history of rheumatoid arthritis
or fume exposure
CT on expiration shows hypodense areas
Diffuse panbronchiolitis Most patients are male and nonsmokers
Almost all have chronic sinusitis
Chest X-ray and HRCT show diffuse small
centrilobular nodular opacities and hyperinflation
Definition of abbreviations: COPD 5 chronic obstructive pulmonary disease;
CT 5 computed tomography; HRCT 5 high-resolution computed tomography.
These features tend to be characteristic of the respective diseases, but do not
occur in every case. For example, a person who has never smoked may develop
COPD (especially in the developing world where other risk factors may be more
important than cigarette smoking); asthma may develop in adult and even
elderly patients.
KEY POINTS
d Reduction of total personal exposure to tobacco smoke,
occupational dusts and chemicals, and indoor and out-
door air pollutants are important goals to prevent the
onset and progression of COPD.
d Smoking cessation is the single most effective—and cost-
effective—intervention in most people to reduce the risk of
developing COPD and stop its progression (Evidence A).
d Comprehensive tobacco control policies and programs
with clear, consistent, and repeated nonsmoking messages
should be delivered through every feasible channel.
d Efforts to reduce smoking through public health initia-
tives should also focus on passive smoking to minimize
risks for nonsmokers.
d Many occupationally induced respiratory disorders can
be reduced or controlled through a variety of strategies
aimed at reducing the burden of inhaled particles and
gases.
d Reducing the risk from indoor and outdoor air pollution
is feasible and requires a combination of public policy
and protective steps taken by individual patients.
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agonist that aids smoking cessation by relieving nicotine with-
drawal symptoms and reducing the rewarding properties of
nicotine, has been demonstrated to be safe and efficacious (80–
82). Special consideration should be given before using phar-
macotherapy in the following selected populations: people with
medical contraindications, light smokers (,10 cigarettes/d), and
pregnant and adolescent smokers.
Occupational exposures. Although it is not known how many
individuals are at risk of developing respiratory disease from
occupational exposures in either developing or developed
countries, many occupationally induced respiratory disorders
can be reduced or controlled through a variety of strategies
aimed at reducing the burden of inhaled particles and gases
(83–85).
The main emphasis should be on primary prevention, which
is best achieved by the elimination or reduction of exposures to
various substances in the workplace. Secondary prevention,
achieved through surveillance and early case detection, is also
of great importance.
Indoor and outdoor air pollution. Individuals experience di-
verse indoor and outdoor environments throughout the day,
each of which has its own unique set of air contaminants and
particulates that cause adverse effects on lung function (86).
Although outdoor and indoor air pollution are generally
considered separately, the concept of total personal exposure
may be more relevant for COPD. Reducing the risk from
indoor and outdoor air pollution is feasible and requires
a combination of public policy and protective steps taken by
individual patients. At the national level, achieving a set level of
air quality standards should be a high priority; this goal will
normally require legislative action. Reduction of exposure to
smoke from biomass fuel, particularly among women and
children, is a crucial goal to reduce the prevalence of COPD
worldwide. Although efficient nonpolluting cooking stoves have
been developed, their adoption has been slow due to social
customs and cost.
The health care provider should consider COPD risk factors,
including smoking history, family history, exposure to indoor/
outdoor pollution, and socioeconomic status, for each individual
patient. Those who are at high risk should avoid vigorous
exercise outdoors during pollution episodes. Persons with
advanced COPD should monitor public announcements of air
quality and be aware that staying indoors when air quality is
poor may help reduce their symptoms. If various solid fuels are
used for cooking and heating, adequate ventilation should be
encouraged. Under most circumstances, vigorous attempts
should be made to reduce exposure through reducing workplace
emissions and improving ventilation measures, rather than
simply using respiratory protection to reduce the risks of
ambient air pollution. Air cleaners have not been shown to
have health benefits, whether directed at pollutants generated
by indoor sources or at those brought in with outdoor air.
Component 3: Manage Stable COPD
Introduction. The overall approach to managing stable COPD
should be characterized by an increase in treatment, depending
on the severity of the disease and the clinical status of the patient.
Management of COPD is based on an individualized assessment
of disease severity and response to various therapies. The clas-
sification of severity of stable COPD incorporates an individual-
ized assessment of disease severity and therapeutic response into
the management strategy. The severity of airflow limitation
provides a general guide to the use of some treatments, but the
TABLE 5. BRIEF STRATEGIES TO HELP THE PATIENT WHO IS
WILLING TO QUIT
1. ASK: Systematically identify all tobacco users at every visit.
Implement an officewide system that ensures that, for EVERY patient at
EVERY clinic visit, tobacco use status is queried and documented.
2. ADVISE: Strongly urge all tobacco users to quit.
In a clear, strong, and personalized manner, urge every tobacco user to quit.
3. ASSESS: Determine willingness to make a quit attempt.
Ask every tobacco user if he or she is willing to make a quit attempt at this
time (e.g., within the next 30 d).
4. ASSIST: Aid the patient in quitting.
Help the patient with a quit plan; provide practical counseling; provide
intratreatment social support; help the patient obtain extratreatment
social support; recommend use of approved pharmacotherapy except
in special circumstances; provide supplementary materials.
5. ARRANGE: Schedule follow-up contact.
Schedule follow-up contact, either in person or via telephone.
Data from References 72–75.
KEY POINTS
d The overall approach to managing stable COPD should
be individualized to address symptoms and improve
quality of life.
d For patients with COPD, health education plays an
important role in smoking cessation (Evidence A) and
can also play a role in improving skills, ability to cope
with illness, and health status.
d None of the existing medications for COPD have been
shown to modify the long-term decline in lung function
that is the hallmark of this disease (Evidence A).
Therefore, pharmacotherapy for COPD is used to de-
crease symptoms and/or complications.
d Bronchodilator medications are central to the symptom-
atic management of COPD (Evidence A). They are
given on an as-needed basis or on a regular basis to
prevent or reduce symptoms and exacerbations.
d The principal bronchodilator treatments are b2-agonists,
anticholinergics, and methylxanthines used singly or in
combination (Evidence A).
d Regular treatment with long-acting bronchodilators is
more effective and convenient than treatment with
short-acting bronchodilators (Evidence A).
d The addition of regular treatment with inhaled glucocor-
ticosteroids to bronchodilator treatment is appropriate for
symptomatic patients with COPD with an FEV1 , 50%
predicted (stage III, severe COPD, and stage IV, very
severe COPD) and repeated exacerbations (Evidence A).
d Chronic treatment with systemic glucocorticosteroids
should be avoided because of an unfavorable benefit-
to-risk ratio (Evidence A).
d In patients with COPD, influenza vaccines can reduce
serious illness (Evidence A). Pneumococcal polysaccha-
ride vaccine is recommended for patients with COPD
who are 65 years and older and for patients with COPD
who are younger than age 65 with an FEV1 , 40%
predicted (Evidence B).
d All patients with COPD benefit from exercise training
programs, improving with respect to both exercise toler-
ance and symptoms of dyspnea and fatigue (Evidence A).
d The long-term administration of oxygen (. 15 h/d) to
patients with chronic respiratory failure has been shown
to increase survival (Evidence A).
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selection of therapy is predominantly determined by the patient’s
symptoms and clinical presentation. Treatment also depends on
the patient’s educational level and willingness to apply the
recommended management, on cultural and local practice con-
ditions, and on the availability of medications.
Education. Although patient education is generally regarded
as an essential component of care for any chronic disease, assess-
ment of the value of education in COPDmay be difficult because
of the relatively long time required to achieve improvements in
objective measurements of lung function. Patient education alone
does not improve exercise performance or lung function (87–90)
(Evidence B), but it can play a role in improving skills, ability to
cope with illness, and health status (91). Patient education re-
garding smoking cessation has the greatest capacity to influence
the natural history of COPD (Evidence A). Education also im-
proves patient response to exacerbations (92, 93) (Evidence B).
Prospective end-of-life discussions can lead to understanding of
advance directives and effective therapeutic decisions at the end
of life (94) (Evidence B).
Ideally, educational messages should be incorporated into all
aspects of care for COPD and may take place in many settings:
consultations with physicians or other health care workers,
home-care or outreach programs, and comprehensive pulmo-
nary rehabilitation programs. Education should be tailored to
the needs and environment of the individual patient, interactive,
directed at improving quality of life, simple to follow, practical,
and appropriate to the intellectual and social skills of the
patient and the caregivers. The topics that seem most appro-
priate for an education program include the following: smoking
cessation; basic information about COPD and pathophysiology
of the disease, general approach to therapy and specific aspects
of medical treatment, self-management skills, strategies to help
minimize dyspnea, advice about when to seek help, self-
management and decision making during exacerbations, and
advance directives and end-of-life issues.
Pharmacologic treatments. Pharmacologic therapy is used to
prevent and control symptoms (Figure 2), reduce the frequency
and severity of exacerbations, improve health status, and
improve exercise tolerance. None of the existing medications
(Table 6) for COPD have been shown to modify the long-term
decline in lung function that is the hallmark of this disease (51,
95–97) (Evidence A). However, this should not preclude efforts
to use medications to control symptoms.
BRONCHODILATORS. Bronchodilator medications are central
to the symptomatic management of COPD (98–101) (Evidence
A) (Table 7). They are given either on an as-needed basis for
relief of persistent or worsening symptoms or on a regular basis
to prevent or reduce symptoms. The side effects of bronchodi-
lator therapy are pharmacologically predictable and dose de-
pendent. Adverse effects are less likely, and resolve more rap-
idly after treatment withdrawal, with inhaled than with oral
treatment. When treatment is given by the inhaled route, atten-
tion to effective drug delivery and training in inhaler technique
are essential.
Bronchodilator drugs commonly used in treating COPD in-
clude b2-agonists, anticholinergics, and methylxanthines. The
choice depends on the availability of the medications and the
patient’s response. All categories of bronchodilators have been
shown to increase exercise capacity inCOPD,without necessarily
producing significant changes in FEV1 (102–105) (Evidence A).
Regular treatment with long-acting bronchodilators is more
effective and convenient than treatment with short-acting bron-
chodilators (106–109) (Evidence A). Regular use of a long-
acting b2-agonist (107) or a short- or long-acting anticholinergic
improves health status (106–108). Treatment with a long-acting
inhaled anticholinergic drug reduces the rate of COPD exacer-
bations (110) and improves the effectiveness of pulmonary re-
habilitation (111). Theophylline is effective in COPD, but, due
to its potential toxicity, inhaled bronchodilators are preferred
when available. All studies that have shown efficacy of theoph-
ylline in COPD were done with slow-release preparations.
Combining bronchodilators with different mechanisms and
durations of action may increase the degree of bronchodilation
for equivalent or lesser side effects. A combination of a short-
acting b2-agonist and an anticholinergic produces greater and
more sustained improvements in FEV1 than either drug alone
and does not produce evidence of tachyphylaxis over 90 days of
treatment (112–114) (Evidence A).
Figure 2. Therapy at each stage of
chronic obstructive pulmonary disease
(COPD). Post-bronchodilator FEV1 is rec-
ommended for the diagnosis and assess-
ment of severity of COPD.
GOLD Executive Summary 541
The combination of a b2-agonist, an anticholinergic, and/or
theophylline may produce additional improvements in lung
function (112–118) and health status (112, 119). Increasing the
number of drugs usually increases costs, and an equivalent
benefit may occur by increasing the dose of one bronchodilator
when side effects are not a limiting factor. Detailed assessments
of this approach have not been performed.
Dose–response relationships using the FEV1 as the outcome
are relatively flat with all classes of bronchodilators (98–101).
Toxicity is also dose related. Increasing the dose of either
a b2-agonist or an anticholinergic by an order of magnitude,
especially when given by a wet nebulizer, appears to provide
subjective benefit in acute episodes (120) (Evidence B) but is
not necessarily helpful in stable disease (121) (Evidence C).
When treatment is given by the inhaled route, attention to
effective drug delivery and training in inhaler technique are
essential. The choice of inhaler device will depend on availabil-
ity, cost, the prescribing physician, and the skills and ability of
the patient. Patients with COPD may have more problems in ef-
fective coordination and find it harder to use a simple metered-
dose inhaler than do healthy volunteers or younger patients
with asthma. It is essential to ensure that inhaler technique is
correct and to recheck this at each visit.
GLUCOCORTICOSTEROIDS. Regular treatment with inhaled
glucocorticosteroids does not modify the long-term decline of
FEV1 in patients with COPD (95–97, 122). However, regular
treatment with inhaled glucocorticosteroids is appropriate for
symptomatic patients with COPD with an FEV1 , 50% pre-
dicted (stages III and IV) and repeated exacerbations (e.g.,
three in the last 3 yr) (123–126) (Evidence A). This treatment
has been shown to reduce the frequency of exacerbations and
thus improve health status (127) (Evidence A), and withdrawal
from treatment with inhaled glucocorticosteroids can lead to
exacerbations in some patients (128). Reanalysis of pooled
data from several longer studies of inhaled glucocorticoste-
roids in COPD suggests that this treatment reduces all-cause
mortality (129), but this conclusion requires confirmation in pro-
spective studies before leading to a change in current treatment
TABLE 7. BRONCHODILATORS IN STABLE CHRONIC
OBSTRUCTIVE PULMONARY DISEASE
d Bronchodilator medications are central to symptom management in COPD.
d Inhaled therapy is preferred.
d The choice among b2-agonist, anticholinergic, theophylline, or
combination therapy depends on availability and individual response in
terms of symptom relief and side effects.
d Bronchodilators are prescribed on an as-needed or on a regular basis to
prevent or reduce symptoms.
d Long-acting inhaled bronchodilators are more effective and convenient.
d Combining bronchodilators may improve efficacy and decrease the risk of
side effects compared to increasing the dose of a single bronchodilator.
Definition of abbreviation: COPD 5 chronic obstructive pulmonary disease.
TABLE 6. COMMONLY USED FORMULATIONS OF MEDICATIONS USED IN CHRONIC OBSTRUCTIVE PULMONARY DISEASE
Medication Inhaler (mg)
Solution for
Nebulizer (mg/ml) Oral
Vials for
Injection (mg)
Duration of
Action (h)
b2-Agonists
Short-acting
Fenoterol 100–200 (MDI) 1 0.5% (syrup) 4–6
Salbutamol (albuterol) 100, 200 (MDI and DPI) 5 5 mg (pill) 0.24% (syrup) 0.1, 0.5 4–6
Terbutaline 400, 500 (DPI) 0.2, 0.25 4–6
Long-acting
Formoterol 4.5–12 (MDI and DPI) 121
Salmeterol 25–50 (MDI and DPI) 121
Anticholinergics
Short-acting
Ipatropium bromide 20, 40 (MDI) 0.25-0.5 6–8
Oxitropium bromide 100 (MDI) 1.5 7–9
Long-acting
Tiotropium 18 (DPI) 241
Combination short-acting
b2-agonists
plus anticholinergic in
one inhaler
Fenoterol/ipratropium 200/80 (MDI) 1.25/0.5 6–8
Salbutamol/ipratropium 75/15 (MDI) 0.75/4.5 6–8
Methylxanthines
Aminophylline 200–600 mg (pill) 240 Variable, up to 24
Theophylline (SR) 100–600 mg (pill) Variable, up to 24
Inhaled glucocorticosteroids
Beclomethasone 50–400 (MDI and DPI) 0.2-0.4
Budesonide 100, 200, 400 (DPI) 0.20, 0.25, 0.5
Fluticasone 50–500 (MDI and DPI)
Triamcinolone 100 (MDI) 40 40
Combination long-acting
b2-agonists plus
glucocorticosteroids
in one inhaler
Formoterol/budesonide 4.5/160, 9/320 (DPI)
Salmeterol/fluticasone 50/100, 250, 500 (DPI) 25/50,
125, 250 (MDI)
Systemic glucocorticosteroids
Prednisone 5–60 mg (pill)
Methylprednisolone 4, 8, 16 mg (pill)
Definition of abbreviation: DPI 5 dry powder inhaler; MDI 5 metered-dose inhaler; SR 5 slow release.
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recommendations. An inhaled glucocorticosteroid combined with
a long-acting b2-agonist is more effective than the individual
components (123, 125, 126, 130, 131) (Evidence A). The dose–
response relationships and long-term safety of inhaled gluco-
corticosteroids in COPD are not known.
Long-term treatment with oral glucocorticosteroids is not
recommended in COPD (Evidence A). A side effect of long-
term treatment with systemic glucocorticosteroids is steroid
myopathy (132–134), which contributes to muscle weakness,
decreased functionality, and respiratory failure in subjects with
advanced COPD.
OTHER PHARMACOLOGIC TREATMENTS. Vaccines. Influenza
vaccines can reduce serious illness (135) and death in patients
with COPD by approximately 50% (136, 137) (Evidence A).
Vaccines containing killed or live, inactivated viruses are re-
commended (138) because they are more effective in elderly
patients with COPD (139). The strains are adjusted each year
for appropriate effectiveness and should be given once each
year (140). Pneumococcal polysaccharide vaccine is recommen-
ded for patients with COPD who are 65 years and older (141,
142). In addition, this vaccine has been shown to reduce the
incidence of community-acquired pneumonia in patients with
COPD who are younger than 65 years with an FEV1 , 40%
predicted (143) (Evidence B).
a1-Antitrypsin augmentation therapy. Young patients with
severe hereditary a1-antitrypsin deficiency and established
emphysema may be candidates for a1-antitrypsin augmentation
therapy. However, this therapy is very expensive, not available
in most countries, and not recommended for patients with COPD
that is unrelated to a1-antitrypsin deficiency (Evidence C).
Antibiotics. Prophylactic, continuous use of antibiotics has
been shown to have no effect on the frequency of exacerbations
in COPD (144–146), and a study that examined the efficacy of
chemoprophylaxis undertaken in the winter months over a pe-
riod of 5 years concluded that there was no benefit (147). There
is no current evidence that the use of antibiotics, other than for
treating infectious exacerbations of COPD and other bacterial
infections, is helpful (148, 149) (Evidence A).
Mucolytic (mucokinetic, mucoregulator) agents (ambroxol,
erdosteine, carbocysteine, iodinated glycerol). The regular use
of mucolytics in COPD has been evaluated in a number of long-
term studies with controversial results (150–152). Although
a few patients with viscous sputum may benefit from mucolytics
(153, 154), the overall benefits seem to be very small, and the
widespread use of these agents cannot be recommended at
present (Evidence D).
Antioxidant agents. Antioxidants, in particular N-acetylcys-
teine, have been reported in small studies to reduce the
frequency of exacerbations, leading to speculation that these
medications could have a role in the treatment of patients with
recurrent exacerbations (155–158) (Evidence B). However,
a large randomized controlled trial found no effect of N-
acetylcysteine on the frequency of exacerbations, except in
patients not treated with inhaled glucocorticosteroids (159).
Immunoregulators (immunostimulators, immunomodulators).
Studies using an immunoregulator in COPD show a decrease in
the severity and frequency of exacerbations (160, 161). How-
ever, additional studies to examine the long-term effects of this
therapy are required before its regular use can be recommended
(162).
Antitussives. Cough, although sometimes a troublesome
symptom in COPD, has a significant protective role (163).
Thus, the regular use of antitussives is not recommended in
stable COPD (Evidence D).
Vasodilators. In patients with COPD, inhaled nitric oxide can
worsen gas exchange because of altered hypoxic regulation of
ventilation–perfusion balance (164, 165). Therefore, based on the
available evidence, nitric oxide is not indicated in stable COPD.
Narcotics (morphine). Oral and parenteral opioids are ef-
fective for treating dyspnea in patients with advanced COPD
disease. There are insufficient data to conclude whether nebu-
lized opioids are effective (166). However, some clinical studies
suggest that morphine used to control dyspnea may have serious
adverse effects and its benefits may be limited to a few sensitive
subjects (167–171).
Others. Nedocromil, leukotriene modifiers, and alternative
healing methods (e.g., herbal medicine, acupunture, homeopa-
thy) have not been adequately tested in patients with COPD
and thus cannot be recommended at this time.
Nonpharmacologic treatments. REHABILITATION. The princi-
pal goals of pulmonary rehabilitation are to reduce symptoms,
improve quality of life, and increase physical and emotional
participation in everyday activities. To accomplish these goals,
pulmonary rehabilitation covers a range of nonpulmonary prob-
lems that may not be adequately addressed by medical therapy
for COPD. Such problems, which especially affect patients with
stages II through IV COPD, include exercise deconditioning,
relative social isolation, altered mood states (especially de-
pression), muscle wasting, and weight loss.
Although more information is needed on criteria for patient
selection for pulmonary rehabilitation programs, patients with
COPD at all stages of disease appear to benefit from exercise
training programs, improving with respect to both exercise
tolerance and symptoms of dyspnea and fatigue (172) (Evidence
A). Data suggest that these benefits can be sustained even after
a single pulmonary rehabilitation program (173–175). Benefit
does wane after a rehabilitation program ends, but if exercise
training ismaintained at home, the patient’s health status remains
above pre-rehabilitation levels (Evidence B). To date, there is no
consensus on whether repeated rehabilitation courses enable
patients to sustain the benefits gained through the initial course.
Benefits have been reported from rehabilitation programs con-
ducted in inpatient, outpatient, and home settings (176–178).
Ideally, pulmonary rehabilitation should involve several
types of health professionals. The components of pulmonary re-
habilitation vary widely from program to program, but a com-
prehensive pulmonary rehabilitation program includes exercise
training, nutrition counseling, and education. Baseline and out-
come assessments of each participant in a pulmonary rehabil-
itation program should be made to quantify individual gains and
target areas for improvement. Assessments should include the
following:
d Detailed history and physical examination
d Measurement of spirometry before and after use of a bron-
chodilator drug
d Assessment of exercise capacity
d Measurement of health status and impact of breathlessness
d Assessment of inspiratory and expiratory muscle strength
and lower limb strength (e.g., quadriceps) in patients who
suffer from muscle wasting
The first two assessments are important for establishing
entry suitability and baseline status but are not used in outcome
assessment. The last three assessments are baseline and out-
come measures.
OXYGEN THERAPY The long-term administration of oxygen
(. 15 h/d) to patients with chronic respiratory failure has been
shown to increase survival (179, 180). It can also have a bene-
ficial impact on hemodynamics, hematologic characteristics,
exercise capacity, lung mechanics, and mental state (181).
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Long-term oxygen therapy is generally introduced in
patients with stage IV COPD, who have
d PaO2 at or below 7.3 kPa (55 mm Hg) or SaO2 at or below
88%, with or without hypercapnia (Evidence B), or
d PaO2 between 7.3 kPa (55 mm Hg) and 8.0 kPa (60 mm Hg),
or SaO2 of 88%, if there is evidence of pulmonary hyperten-
sion, peripheral edema suggesting congestive cardiac failure,
or polycythemia (hematocrit. 55%) (Evidence D).
The primary goal of oxygen therapy is to increase the
baseline PaO2 to at least 8.0 kPa (60 mm Hg) at sea level and
rest, and/or produce an SaO2 of at least 90%, which will preserve
vital organ function by ensuring adequate delivery of oxygen. A
decision about the use of long-term oxygen should be based on
the waking PaO2 values. The prescription should always include
the source of supplemental oxygen (gas or liquid), method of
delivery, duration of use, and flow rate at rest, during exercise,
and during sleep.
VENTILATORY SUPPORT. Although long-term noninvasive
positive-pressure ventilation (NIPPV) cannot be recommended
for the routine treatment of patients with chronic respiratory
failure due to COPD, the combination of NIPPV with long-term
oxygen therapy may be of some use in a selected subset of
patients, particularly in those with pronounced daytime hyper-
capnia (182).
SURGICAL TREATMENTS. Bullectomy. In carefully selected
patients, this procedure is effective in reducing dyspnea and
improving lung function (183) (Evidence C). A thoracic CT
scan, arterial blood gas measurement, and comprehensive re-
spiratory function tests are essential before making a decision
regarding suitability for resection of a bulla.
Lung volume reduction surgery. A large multicenter study
of 1,200 patients comparing lung volume reduction surgery
with medical treatment has shown that after 4.3 years, patients
with upper lobe emphysema and low exercise capacity who
received the surgery had a greater survival rate than similar
patients who received medical therapy (54 vs. 39.7%) (184). In
addition, the surgery patients experienced greater improvements
in their maximal work capacity and their health-related quality of
life. The advantage of surgery over medical therapy was less
significant among patients who had other emphysema distribution
or high exercise capacity before treatment.Although the results of
this study showed some very positive results of surgery in a select
group of patients (69, 184), lung volume reduction surgery is an
expensive palliative surgical procedure and can be recommended
only in carefully selected patients.
Lung transplantation. In appropriately selected patients with
very advanced COPD, lung transplantation has been shown to
improve quality of life and functional capacity (185–188)
(Evidence C). Criteria for referral for lung transplantation
include FEV1 , 35% predicted, PaO2 , 7.3–8.0 kPa (55–60
mm Hg), PaCO2 . 6.7 kPa (50 mm Hg), and secondary
pulmonary hypertension (189, 190).
Special considerations. SURGERY IN COPD. Postoperative
pulmonary complications are as important and common as
postoperative cardiac complications and, consequently, are
a key component of the increased risk posed by surgery in
patients with COPD. The principal potential factors contribut-
ing to the risk include smoking, poor general health status, age,
obesity, and COPD severity. A comprehensive definition of
postoperative pulmonary complications should include only
major pulmonary respiratory complications, namely lung infec-
tions, atelectasis, and/or increased airflow obstruction, all
potentially resulting in acute respiratory failure and aggravation
of underlying COPD (191–196).
Component 4: Manage Exacerbations
Introduction. COPD is often associated with exacerbations
of symptoms (197–201). An exacerbation of COPD is defined as
‘‘an event in the natural course of the disease characterized by
a change in the patient’s baseline dyspnea, cough, and/or
sputum that is beyond normal day-to-day variations, is acute
in onset, and may warrant a change in regular medication in
a patient with underlying COPD’’ (202, 203). Exacerbations are
categorized in terms of either clinical presentation (number of
symptoms [199]) and/or heath care resources utilization (202).
The impact of exacerbations is significant and a patient’s
symptoms and lung function may both take several weeks to
recover to the baseline values (204).
The most common causes of an exacerbation are infection of
the tracheobronchial tree and air pollution (205), but the cause
of approximately one-third of severe exacerbations cannot be
identified. The role of bacterial infections is controversial, but
recent investigations have shown that at least 50% of patients
have bacteria in high concentrations in their lower airways
during exacerbations (206–208). Development of specific im-
mune responses to the infecting bacterial strains, and the
association of neutrophilic inflammation with bacterial exacer-
bations, also support the bacterial causation of a proportion of
exacerbations (209–212).
Diagnosis and assessment of severity. MEDICAL HISTORY. In-
creased breathlessness, the main symptom of an exacerbation, is
often accompanied by wheezing and chest tightness, increased
cough and sputum, change of the color and/or tenacity of
sputum, and fever. Exacerbations may also be accompanied
by a number of nonspecific complaints, such as tachycardia and
tachypnea, malaise, insomnia, sleepiness, fatigue, depression,
KEY POINTS
d An exacerbation of COPD is defined as an event in the
natural course of the disease characterized by a change in
the patient’s baseline dyspnea, cough, and/or sputum that
is beyond normal day-to-day variations, is acute in onset,
and may warrant a change in regular medication in
a patient with underlying COPD.
d The most common causes of an exacerbation are in-
fection of the tracheobronchial tree and air pollution,
but the cause of about one-third of severe exacerbations
cannot be identified (Evidence B).
d Inhaled bronchodilators (particularly inhaled b2-agonists
with or without anticholinergics) and oral glucocorticos-
teroids are effective treatments for exacerbations of
COPD (Evidence A).
d Patients experiencing COPD exacerbations with clinical
signs of airway infection (e.g., increased sputum purulence)
may benefit from antibiotic treatment (Evidence B).
d Noninvasive mechanical ventilation in exacerbations
improves respiratory acidosis, increases pH, decreases
the need for endotracheal intubation, and reduces PaCO2,
respiratory rate, severity of breathlessness, the length of
hospital stay, and mortality (Evidence A).
d Medications and education to help prevent future exac-
erbations should be considered as part of follow-up,
because exacerbations affect the quality of life and
prognosis of patients with COPD.
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and confusion. A decrease in exercise tolerance, fever, and/or
new radiologic anomalies suggestive of pulmonary disease may
herald a COPD exacerbation. An increase in sputum volume
and purulence points to a bacterial cause, as does prior history
of chronic sputum production (199, 212).
ASSESSMENT OF SEVERITY. Assessment of the severity of an
exacerbation is based on the patient’s medical history before the
exacerbation, preexisting comorbidities, symptoms, physical
examination, arterial blood gas measurements, and other labo-
ratory tests. Physicians should obtain the results of previous
evaluations, where possible, to compare with the current clinical
data. Specific information is required on the frequency and
severity of attacks of breathlessness and cough, sputum volume
and color, and limitation of daily activities. When available,
prior arterial blood gas measurements are extremely useful for
comparison with those made during the acute episode, as an
acute change in these tests is more important than their absolute
values. Thus, where possible, physicians should instruct their
patients to bring the summary of their last evaluation when they
come to the hospital with an exacerbation. In patients with stage
IV COPD, the most important sign of a severe exacerbation is
a change in the mental status of the patient and this signals
a need for immediate evaluation in the hospital.
Spirometry and PEF. Even simple spirometric tests can be
difficult for a sick patient to perform properly. These measure-
ments are not accurate during an acute exacerbation; therefore,
their routine use is not recommended.
Pulse oximetry and arterial blood gas measurement. Pulse
oximetry can be used to evaluate a patient’s oxygen saturation
and need for supplemental oxygen therapy. For patients that
require hospitalization, measurement of arterial blood gases is
important to assess the severity of an exacerbation. A PaO2 ,
8.0 kPa (60 mm Hg) and/or SaO2 , 90% with or without PaCO2
. 6.7 kPa (50 mm Hg) when breathing room air indicate
respiratory failure. In addition, moderate to severe acidosis
(pH , 7.36) plus hypercapnia (PaCO2 . 6–8 kPa, 45–60 mm Hg)
in a patient with respiratory failure is an indication for
mechanical ventilation (196, 213).
Chest X-ray and ECG. Chest radiographs (posterior/ante-
rior plus lateral) are useful in identifying alternative diagnoses
that can mimic the symptoms of an exacerbation. An ECG aids
in the diagnosis of right heart hypertrophy, arrhythmias, and
ischemic episodes. Pulmonary embolism can be very difficult to
distinguish from an exacerbation, especially in advanced
COPD, because right ventricular hypertrophy and large pulmo-
nary arteries lead to confusing ECG and radiographic results. A
low systolic blood pressure and an inability to increase the PaO2
above 8.0 kPa (60 mm Hg) despite high-flow oxygen also
suggest pulmonary embolism. If there are strong indications
that pulmonary embolism has occurred, it is best to treat for this
together with the exacerbation.
Other laboratory tests. The complete blood count may iden-
tify polycythemia (hematocrit . 55%) or suggest bleeding.
White blood cell counts are usually not very informative. The
presence of purulent sputum during an exacerbation of symp-
toms is sufficient indication for starting empirical antibiotic
treatment (33). Streptococcus pneumoniae, Hemophilus influen-
zae, and Moraxella catarrhalis are the most common bacterial
pathogens involved in COPD exacerbations. If an infectious
exacerbation does not respond to the initial antibiotic treatment,
a sputum culture and an antibiogram should be performed.
Biochemical test abnormalities can be associated with an
exacerbation and include electrolyte disturbance(s) (e.g., hypo-
natremia, hypokalemia), poor glucose control, or metabolic
acid–base disorder. These abnormalities can also be due to
associated comorbid conditions.
DIFFERENTIAL DIAGNOSES. Patients with apparent exacerba-
tions of COPD who do not respond to treatment (204, 214)
should be reevaluated for other medical conditions that can
aggravate symptoms or mimic COPD exacerbations (153),
including pneumonia, congestive heart failure, pneumothorax,
pleural effusion, pulmonary embolism, and cardiac arrhythmia.
Noncompliance with the prescribed medication regimen can
also cause increased symptoms that may be confused with a true
exacerbation. Elevated serum levels of brain-type natriuretic
peptide, in conjunction with other clinical information, can
identify patients with acute dyspnea secondary to congestive
heart failure and enable them to be distinguished from patients
with COPD exacerbations (215, 216).
Home management. There is increasing interest in home care
for patients with end-stage COPD, although the exact criteria
for this approach as opposed to hospital treatment remain
uncertain and will vary by health care setting (217–220).
BRONCHODILATOR THERAPY. Home management of COPD
exacerbations involves increasing the dose and/or frequency of
existing short-acting bronchodilator therapy, preferably with
a b2-agonist (Evidence A). If not already used, an anticholin-
ergic can be added until the symptoms improve (Evidence D).
GLUCOCORTICOSTEROIDS. Systemic glucocorticosteroids are
beneficial in the management of exacerbations of COPD. They
shorten recovery time, improve lung function (FEV1) and
hypoxemia (PaO2) (221–224) (Evidence A), and may reduce
the risk of early relapse, treatment failure, and length of
hospital stay (225). They should be considered in addition to
bronchodilators if the patient’s baseline FEV1 is less than 50%
predicted. A dose of 30 to 40 mg prednisolone per day for 7 to
10 days is recommended (221, 222, 226).
ANTIBIOTICS. The use of antibiotics in the management of
COPD exacerbations is discussed below in HOSPITAL MANAGE-
MENT.
Hospital management. The risk of dying of an exacerbation
of COPD is closely related to the development of respiratory
acidosis, the presence of significant comorbidities, and the need
for ventilatory support (227). Patients lacking these features are
not at high risk of dying, but those with severe underlying
COPD often require hospitalization in any case. Attempts at
managing such patients entirely in the community have met
with only limited success (228), but returning them to their
homes with increased social support and a supervised medical
care package after initial emergency room assessment has been
much more successful (229). Savings on inpatient expenditures
(230) offset the additional costs of maintaining a community-
based COPD nursing team. However, detailed cost–benefit
analyses of these approaches are awaited.
A range of criteria to consider for hospital assessment/
admission for exacerbations of COPD are shown in Table 8.
Some patients need immediate admission to an intensive care
unit (ICU) (Table 9). Admission of patients with severe COPD
exacerbations to intermediate or special respiratory care units
may be appropriate if personnel, skills, and equipment exist to
identify and manage acute respiratory failure successfully.
The first actions when a patient reaches the emergency
department are to provide supplemental oxygen therapy and
to determine whether the exacerbation is life threatening. If so,
the patient should be admitted to the ICU immediately. Other-
wise, the patient may be managed in the emergency department
or hospital (Table 10).
CONTROLLED OXYGEN THERAPY. Oxygen therapy is the cor-
nerstone of hospital treatment of COPD exacerbations. Sup-
plemental oxygen should be titrated to improve the patient’s
hypoxemia. Adequate levels of oxygenation (PaO2 . 8.0 kPa, 60
mm Hg, or SaO2 . 90%) are easy to achieve in uncomplicated
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exacerbations, but CO2 retention can occur insidiously with
little change in symptoms. Once oxygen is started, arterial blood
gases should be checked 30 to 60 minutes later to ensure
satisfactory oxygenation without CO2 retention or acidosis.
Venturi masks (high-flow devices) offer more accurate delivery
of controlled oxygen than do nasal prongs but are less likely to
be tolerated by the patient (196).
BRONCHODILATOR THERAPY. Short-acting inhaled b2-agonists
are usually the preferred bronchodilators for treatment of
exacerbations of COPD (153, 196, 231) (Evidence A). If
a prompt response to these drugs does not occur, the addition
of an anticholinergic is recommended, even though evidence
concerning the effectiveness of this combination is controver-
sial. Despite its widespread clinical use, the role of methylxan-
thines in the treatment of exacerbations of COPD remains
controversial. Intravenous methylxanthines (theophylline or
aminohylline) are currently considered second-line therapy,
used when there is inadequate or insufficient response to
short-acting bronchodilators (232–236) (Evidence B). Possible
beneficial effects in terms of lung function and clinical end-
points are modest and inconsistent, whereas adverse effects are
significantly increased (237, 238). There are no clinical studies
that have evaluated the use of inhaled long-acting bronchodi-
lators (either b2-agonists or anticholinergics) with or without
inhaled glucocorticosteroids during an acute exacerbation.
GLUCOCORTICOSTEROIDS. Oral or intravenous glucocorticos-
teroids are recommended as an addition to other therapies in
the hospital management of exacerbations of COPD (222, 223)
(Evidence A). The exact dose that should be recommended is
not known, but high doses are associated with a significant risk
of side effects. Thirty to 40 mg of oral prednisolone daily for
7 to 10 days is effective and safe (Evidence C). Prolonged treat-
ment does not result in greater efficacy and increases the risk of
side effects.
ANTIBIOTICS. On the basis of the current available evidence
(196, 62), antibiotics should be given to the following individuals:
d Patients with exacerbations of COPD with the following
three cardinal symptoms: increased dyspnea, increased spu-
tum volume, and increased sputum purulence (Evidence B)
d Patients with exacerbations of COPD with two of the
cardinal symptoms, if increased purulence of sputum is
one of the two symptoms (Evidence C)
d Patients with a severe exacerbation of COPD that requires
mechanical ventilation (invasive or noninvasive) (Evidence B)
The infectious agents in COPD exacerbations can be viral or
bacterial (140, 239). The predominant bacteria recovered from
the lower airways of patients with COPD exacerbations are H.
influenzae, S. pneumoniae, andM. catarrhalis (140, 206, 207, 240).
So-called atypical pathogens, such as Mycoplasma pneumoniae
and Chlamydia pneumoniae (240, 241), have been identified in
patients with COPD exacerbations, but because of diagnostic
limitations the true prevalence of these organisms is not known.
RESPIRATORY STIMULANTS. Respiratory stimulants are not
recommended for acute respiratory failure (231). Doxapram,
a nonspecific but relatively safe respiratory stimulant available
in some countries as an intravenous formulation, should be used
only when noninvasive intermittent ventilation is not available
or not recommended (242).
VENTILATORY SUPPORT. The primary objectives of mechani-
cal ventilatory support in patients with COPD exacerbations are
to decrease mortality and morbidity and to relieve symptoms.
Ventilatory support includes both noninvasive intermittent
ventilation using either negative- or positive-pressure devices,
and invasive (conventional) mechanical ventilation by orotra-
cheal tube or tracheostomy.
Noninvasive mechanical ventilation. Noninvasive intermit-
tent ventilation (NIV) has been studied in several randomized
controlled trials in acute respiratory failure, consistently pro-
viding positive results, with success rates of 80 to 85% (182,
243–245). These studies provide evidence that NIV improves
respiratory acidosis (increases pH, and decreases PaCO2), and
decreases respiratory rate, severity of breathlessness, and length
of hospital stay (Evidence A). More importantly, mortality —or
TABLE 8. INDICATIONS FOR HOSPITAL ASSESSMENT OR
ADMISSION FOR EXACERBATIONS OF CHRONIC
OBSTRUCTIVE PULMONARY DISEASE*
d Marked increase in intensity of symptoms, such as sudden development
of resting dyspnea, change in vital signs
d Severe underlying COPD
d Onset of new physical signs (e.g., cyanosis, peripheral edema)
d Failure of exacerbation to respond to initial medical management
d Significant comorbidities
d Frequent exacerbations
d Newly occurring arrhythmias
d Diagnostic uncertainty
d Older age
d Insufficient home support
Definition of abbreviation: COPD 5 chronic obstructive pulmonary disease.
* Local resources need to be considered.
TABLE 9. INDICATIONS FOR INTENSIVE CARE UNIT
ADMISSION OF PATIENTS WITH EXACERBATIONS
OF CHRONIC OBSTRUCTIVE PULMONARY DISEASE*
d Severe dyspnea that responds inadequately to initial emergency therapy
d Changes in mental status (confusion, lethargy, coma)
d Persistent or worsening hypoxemia (PaO2 , 5.3 kPa, 40 mm Hg), and/or
severe/worsening hypercapnia (PaCO2 . 8.0 kPa, 60 mm Hg), and/or
severe/worsening respiratory acidosis (pH , 7.25) despite supplemental
oxygen and noninvasive ventilation
d Need for invasive mechanical ventilation
d Hemodynamic instability—need for vasopressors
* Local resources need to be considered.
TABLE 10. MANAGEMENT OF SEVERE BUT NOT
LIFE-THREATENING EXACERBATIONS OF CHRONIC
OBSTRUCTIVE PULMONARY DISEASE IN THE EMERGENCY
DEPARTMENT OR THE HOSPITAL*
d Assess severity of symptoms, blood gases, chest X-ray
d Administer controlled oxygen therapy and repeat arterial blood gas
measurement after 30–60 min
d Bronchodilators:
– Increase doses and/or frequency
– Combine b2-agonists and anticholinergics
– Use spacers or air-driven nebulizers
– Consider adding intravenous methylxanthines, if needed
d Add oral or intravenous glucocorticosteroids
d Consider antibiotics (oral or occasionally intravenous) when there are
signs of bacterial infection
d Consider noninvasive mechanical ventilation
d At all times:
– Monitor fluid balance and nutrition
– Consider subcutaneous heparin
– Identify and treat associated conditions (e.g., heart failure, arrhythmias)
– Closely monitor condition of the patient
Data from Reference 226.
* Local resources need to be considered.
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its surrogate, intubation rate—is reduced by this intervention
(245–248). However, NIV is not appropriate for all patients, as
summarized in Table 11 (182).
Invasive mechanical ventilation. The indications for initiat-
ing invasive mechanical ventilation during exacerbations of
COPD are shown in Table 12 and include failure of an initial
trial of NIV (252). As experience is being gained with the
generalized clinical use of NIV in COPD, several of the
indications for invasive mechanical ventilation are being suc-
cessfully treated with NIV.
The use of invasive ventilation in patients with end-stage
COPD is influenced by the likely reversibility of the precipitat-
ing event, the patient’s wishes, and the availability of intensive
care facilities. Major hazards include the risk of ventilator-
acquired pneumonia (especially when multiresistant organisms
are prevalent), barotrauma, and failure to wean to spontaneous
ventilation. Contrary to some opinions, acute mortality among
patients with COPD with respiratory failure is lower than
mortality among patients ventilated for non-COPD causes
(253). When possible, a clear statement of the patient’s own
treatment wishes—an advance directive or ‘‘living will’’—makes
these difficult decisions much easier to resolve.
Weaning or discontinuation from mechanical ventilation can
be particularly difficult and hazardous in patients with COPD
and the best method (pressure support or a T-piece trial)
remains a matter of debate (254–256). In patients with COPD
who fail weaning trials, noninvasive ventilation facilitates
extubation. It can also prevent reintubation in patients with
extubation failure and may reduce mortality.
OTHER MEASURES. Further treatments that can be used in the
hospital include the following: fluid administration (accurate
monitoring of fluid balance is essential); nutrition (supplemen-
tary when needed); deep venous thrombosis prophylaxis (me-
chanical devices, heparins, etc.) in immobilized, polycythemic,
or dehydrated patients with or without a history of thrombo-
embolic disease; and sputum clearance (by stimulating coughing
and low-volume forced expirations as in home management).
Manual or mechanical chest percussion and postural drainage
may be beneficial in patients with excessive sputum production
or with lobar atelectasis.
Hospital discharge and follow-up. Insufficient clinical data
exist to establish the optimal duration of hospitalization in
individual patients who develop an exacerbation of COPD (197,
257, 258). Consensus and limited data support the discharge
criteria listed in Table 13. Table 14 provides items to include in
a follow-up assessment 4 to 6 weeks after discharge from the
hospital. Thereafter, follow-up is the same as for patients with
stable COPD, including supervising smoking cessation, moni-
toring the effectiveness of each drug treatment, and monitoring
changes in spirometric parameters (229). Home visits by
a community nurse may permit earlier discharge of patients
hospitalized with an exacerbation of COPD, without increasing
readmission rates (153, 259–261).
In patients who are hypoxemic during a COPD exacerba-
tion, arterial blood gases and/or pulse oximetry should be
evaluated before hospital discharge and in the following 3
months. If the patient remains hypoxemic, long-term supple-
mental oxygen therapy may be required.
Opportunities for prevention of future exacerbations should
be reviewed before discharge, with particular attention to
smoking cessation, current vaccination (influenza, pneumococ-
cal vaccines), knowledge of current therapy including inhaler
technique (32, 262, 263), and how to recognize symptoms of
exacerbations. Pharmacotherapy known to reduce the number
of exacerbations and hospitalizations and delay the time of first/
next hospitalization, such as long-acting inhaled bronchodilators,
inhaled glucocorticosteroids, and combination inhalers, should
be specifically considered. Social problems should be discussed
and principal caregivers identified if the patient has a significant
persisting disability.
4. TRANSLATING GUIDELINE RECOMMENDATIONS TO
THE CONTEXT OF (PRIMARY) CARE
TABLE 11. INDICATIONS AND RELATIVE CONTRAINDICATIONS
FOR NONINVASIVE INTERMITTENT VENTILATION
Selection criteria
d Moderate to severe dyspnea with use of accessory muscles and
paradoxical abdominal motion
d Moderate to severe acidosis (pH < 7.35) and/or hypercapnia
(PaCO2 . 6.0 kPa, 45 mm Hg) (251)
d Respiratory frequency . 25 breaths/min
Exclusion criteria (any may be present)
d Respiratory arrest
d Cardiovascular instability (hypotension, arrhythmias, myocardial infarction)
d Change in mental status; uncooperative patient
d High aspiration risk
d Viscous or copious secretions
d Recent facial or gastroesophageal surgery
d Craniofacial trauma
d Fixed nasopharyngeal abnormalities
d Burns
d Extreme obesity
Data from References 196, 243, 249, and 250.
TABLE 12. INDICATIONS FOR INVASIVE
MECHANICAL VENTILATION
d Unable to tolerate NIV or NIV failure (or exclusion criteria, see Table 11)
d Severe dyspnea with use of accessory muscles and paradoxical
abdominal motion
d Respiratory frequency . 35 breaths/min
d Life-threatening hypoxemia
d Severe acidosis (pH , 7.25) and/or hypercapnia (PaCO2 . 8.0 kPa, 60 mm Hg)
d Respiratory arrest
d Worsening in mental status despite optimal therapy
d Cardiovascular complications (hypotension, shock)
d Other complications (metabolic abnormalities, sepsis, pneumonia,
pulmonary embolism, barotrauma, massive pleural effusion)
Definition of abbreviation: NIV 5 noninvasive intermittent ventilation.
KEY POINTS
d There is considerable evidence that management of
COPD is generally not in accordance with current guide-
lines. Better dissemination of guidelines and their effec-
tive implementation in a variety of health care settings are
urgently required.
d In many countries, primary care practitioners treat the
vast majority of patients with COPD and may be actively
involved in public health campaigns and in bringing
messages about reducing exposure to risk factors to both
patients and the public.
d Spirometric confirmation is a key component of the di-
agnosis of COPD and primary care practitioners should
have access to high-quality spirometry.
d Older patients frequently have multiple chronic health
conditions. Comorbidities can magnify the impact of
COPD on a patient’s health status, and can complicate
the management of COPD.
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The recommendations provided in sections 1 through 3
define—from a disease perspective—best practices in the di-
agnosis, monitoring, and treatment of COPD. However, (pri-
mary) medical care is based on an engagement with patients,
and this engagement determines the success or failure of
pursuing best practice. For this reason, medical practice
requires a translation of disease-specific recommendations to
the circumstances of individual patients—with regard to the
local communities in which they live, and the health systems
from which they receive medical care.
Diagnosis
In pursuing early diagnosis, a policy of identifying patients at
high risk of COPD, followed by watchful surveillance of these
patients, is advised.
Respiratory symptoms. Of the chronic symptoms character-
istic of COPD (dyspnea, cough, sputum production), dyspnea is
the symptom that interferes most with a patient’s daily life and
health status. When taking the medical history of the patient, it
is therefore important to explore the impact of dyspnea and
other symptoms on daily activities, work, and social activities,
and provide treatment accordingly.
Spirometry. High-quality spirometry in primary care is pos-
sible (264, 265), provided that good skills training and an
ongoing quality assurance program are provided. An alternative
is to ensure that high-quality spirometry is available in the
community—for example, within the primary care practice
itself, in a primary care laboratory, or in a hospital setting,
depending on the structure of the local health care system (266).
Ongoing collaboration between primary care and respiratory
care also helps assure quality control.
Comorbidities
Older patients frequently have multiple chronic health condi-
tions and the severity of comorbid conditions and their impact
on a patient’s health status will vary between patients and in the
same patient over time. Comorbidities for patients with COPD
may include the following: other smoking-related diseases, such
as ischemic heart disease and lung cancer; conditions that arise
as a complication of a specific preexisting disease, such as
pulmonary hypertension and consequent heart failure; coexist-
ing chronic conditions with unrelated pathogenesis related to
aging, such as bowel or prostate cancer, depression, diabetes
mellitus, Parkinson’s disease, dementia, and arthritis; or acute
illnesses that may have a more severe impact in patients with
a given chronic disease. For example, upper respiratory tract
infections are the most frequent health problem in all age
groups, but they may have a more severe impact or require
different treatment in patients with COPD.
Reducing Exposure to Risk Factors
Reduction of total personal exposure to tobacco smoke, occu-
pational dusts and chemicals, and indoor and outdoor air
pollutants, including smoke from cooking over biomass-fueled
fires, is an important goal to prevent the onset and progression
of COPD. In many health care systems, primary care practi-
tioners may be actively involved in public health campaigns and
can play an important part in bringing messages about reducing
exposure to risk factors to patients and the public. Primary care
practitioners can also play a very important role in reinforcing
the dangers of passive smoking and the importance of imple-
menting smoke-free work environments.
Smoking cessation is the most effective intervention to
reduce the risk of developing COPD, and simple smoking
cessation advice from health care professionals has been shown
to make patients more likely to stop smoking. Primary care
practitioners often have many contacts with a patient over time,
which provides the opportunity to discuss smoking cessation,
enhance motivation for quitting, and identify the need for
supportive pharmacologic treatment. It is very important to
align the advice given by individual practitioners with public
health campaigns to send a coherent message to the public.
Implementation of COPD Guidelines
GOLD national leaders play an essential role in the dissemi-
nation of information about prevention, early diagnosis, and
management of COPD in health systems around the world. A
major GOLD program activity that has helped to bring together
health care teams at the local level is World COPD Day, held
annually on the third Wednesday in November.* GOLD na-
tional leaders, often in concert with local physicians, nurses, and
health care planners, have hosted many types of activities to
raise awareness of COPD. WONCA (the World Organization of
Family Doctors) is also an active collaborator in organizing World
COPD Day activities. Increased participation of a wide variety of
health care professionals in World COPD Day activities in many
countries would help to increase awareness of COPD.
GOLD is a partner organization in the World Health
Organization’s GARD with the goal to raise awareness of the
burden of chronic respiratory diseases in all countries of the
world, and to disseminate and implement recommendations
from international guidelines.
Although awareness and dissemination of guidelines are
important goals, the actual implementation of a comprehensive
care system inwhich to coordinate themanagement ofCOPDwill
be important to pursue. Evidence is increasing that a chronic
disease management program for patients with COPD that
incorporates a variety of interventions, includes pulmonary re-
habilitation, and is implemented by primary care reduces hospital
admissions and bed days. Key elements are patient participation
and information sharing among health care providers (267).
*For further information on World COPD Day: http://www.goldcopd.org/WCDindex.
asp.
TABLE 13. DISCHARGE CRITERIA FOR PATIENTS WITH
EXACERBATIONS OF CHRONIC OBSTRUCTIVE
PULMONARY DISEASE
d Inhaled b2-agonist therapy is required no more frequently than every 4 h
d Patient, if previously ambulatory, is able to walk across room
d Patient is able to eat and sleep without frequent awakening by dyspnea
d Patient has been clinically stable for 12–24 h
d Arterial blood gases have been stable for 12–24 h
d Patient (or home caregiver) fully understands correct use of medications
d Follow-up and home care arrangements have been completed
(e.g., visiting nurse, oxygen delivery, meal provisions)
d Patient, family, and physician are confident patient can manage successfully
at home
TABLE 14. ITEMS TO ASSESS AT FOLLOW-UP VISIT 4–6 WEEKS
AFTER DISCHARGE FROM HOSPITAL FOR EXACERBATIONS OF
CHRONIC OBSTRUCTIVE PULMONARY DISEASE
d Ability to cope in usual environment
d Measurement of FEV1
d Reassessment of inhaler technique
d Understanding of recommended treatment regimen
d Need for long-term oxygen therapy and/or home nebulizer (for patients
with stage IV, very severe COPD)
Definition of abbreviation: COPD 5 chronic obstructive pulmonary disease.
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